Aripiprazole for the management of schizophrenia in the Japanese population: a systematic review and meta-analysis of randomized controlled trials

Código QR

Aripiprazole for the management of schizophrenia in the Japanese population: a systematic review and meta-analysis of randomized controlled trials

Taro Kishi, Yuki Matsuda, Shinji Matsunaga, Nakao Iwata Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan Background: We conducted a systematic review and meta-analysis of randomized controlled trials comparing aripiprazole with pooled antipsychotics in...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kishi T, Matsuda Y, Matsunaga S, Iwata N
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/a4c3798490b54d0498bc314e7e68527a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Efficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trials
por: Oya K, et al.
Publicado: (2015)

A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders
por: Kishi T, et al.
Publicado: (2016)

Iminodibenzyl class antipsychotics for schizophrenia: a systematic review and meta-analysis of carpipramine, clocapramine, and mosapramine
por: Kishi T, et al.
Publicado: (2014)

Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: a network meta-analysis in a Japanese population
por: Kishi T, et al.
Publicado: (2017)

Efficacy and tolerability of topiramate-augmentation therapy for schizophrenia: a systematic review and meta-analysis of randomized controlled trials
por: Okuyama Y, et al.
Publicado: (2016)

Early prediction of blonanserin response in Japanese patients with schizophrenia
por: Kishi T, et al.
Publicado: (2014)

Memantine treatment for Japanese patients with moderate to severe Alzheimer’s disease: a meta-analysis of double-blind, randomized, placebo-controlled trials
por: Kishi T, et al.
Publicado: (2018)

Role of aripiprazole in treatment-resistant schizophrenia
por: Mossaheb N, et al.
Publicado: (2012)

Memantine for the treatment of frontotemporal dementia: a meta-analysis
por: Kishi T, et al.
Publicado: (2015)

Aripiprazole-associated tic in a schizophrenia patient
por: Guo X, et al.
Publicado: (2015)

Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection
por: Wang SM, et al.
Publicado: (2014)

Association analysis of the Cadherin13 gene with schizophrenia in the Japanese population
por: Otsuka I, et al.
Publicado: (2015)

Paliperidone extended-release tablets in Chinese patients with schizophrenia: meta-analysis of randomized controlled trials
por: Cai SL, et al.
Publicado: (2015)

Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study
por: Wani RA, et al.
Publicado: (2015)

Efficacy, acceptability, and safety of adjunctive aripiprazole in treatment-resistant depression: a meta-analysis of randomized controlled trials
por: Luan SX, et al.
Publicado: (2018)

Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study [Corrigendum]
por: Wani RA, et al.
Publicado: (2015)

The effects of memantine on behavioral disturbances in patients with Alzheimer's disease: a meta-analysis
por: Kishi T, et al.
Publicado: (2017)

Efficacy and safety of aripiprazole once-monthly in obese and nonobese patients with schizophrenia: a post hoc analysis
por: De Hert M, et al.
Publicado: (2015)

Combination treatment with risperidone long-acting injection and psychoeducational approaches for preventing relapse in schizophrenia
por: Zhao Y, et al.
Publicado: (2013)

Melatonin receptor agonists—ramelteon and melatonin—for bipolar disorder: a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials
por: Kishi T, et al.
Publicado: (2019)

Cilostazol for secondary stroke prevention: systematic review and meta-analysis
por: Leonard LL Yeo, et al.
Publicado: (2021)

Comparing the influences of age and disease on the Brief Assessment of Cognition in Schizophrenia in Japanese patients with schizophrenia
por: Kaneda A, et al.
Publicado: (2013)

Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials
por: Kishi T, et al.
Publicado: (2018)

An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia
por: Giorgio L Colombo, et al.
Publicado: (2008)

Parkinson’s disease patients benefit from bicycling - a systematic review and meta-analysis
por: Marianne Tiihonen, et al.
Publicado: (2021)

Worsened hypertension control induced by aripiprazole
por: Yasui-Furukori N, et al.
Publicado: (2013)

Disentangling the neural correlates of corticobasal syndrome and corticobasal degeneration with systematic and quantitative ALE meta-analyses
por: Franziska Albrecht, et al.
Publicado: (2017)

Adherence and rehospitalizations in patients with schizophrenia: evidence from Japanese claims data
por: Kuwabara H, et al.
Publicado: (2015)

Clinical utility of DaTscan in patients with suspected Parkinsonian syndrome: a systematic review and meta-analysis
por: Danny Bega, et al.
Publicado: (2021)

Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson’s disease trial
por: Howard E. Gendelman, et al.
Publicado: (2017)

Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole
por: Izchak Kohen, et al.
Publicado: (2010)

Aripiprazole: from pharmacological profile to clinical use
por: Di Sciascio G, et al.
Publicado: (2015)

Clozapine-induced seizures, electroencephalography abnormalities, and clinical responses in Japanese patients with schizophrenia
por: Kikuchi YS, et al.
Publicado: (2014)

Efficacy and safety of immunosuppressive therapy in myelin oligodendrocyte glycoprotein antibody–associated disease: a systematic review and meta-analysis
por: Qi-Lun Lai, et al.
Publicado: (2021)

Adjunctive treatment with aripiprazole for risperidone-induced hyperprolactinemia
por: Ranjbar F, et al.
Publicado: (2015)

Augmentation treatment in major depressive disorder: focus on aripiprazole
por: J Craig Nelson, et al.
Publicado: (2008)

Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
por: Kishi T, et al.
Publicado: (2017)

A systematic review of quality of life and weight gain-related issues in patients treated for severe and persistent mental disorders: focus on aripiprazole
por: Salvatore Gentile
Publicado: (2009)

Antiplatelet vs. Anticoagulation in Cervical Artery Dissection: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Sihua Liu, et al.
Publicado: (2021)

Not all partial dopamine D2 receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse
por: Athan Spiros, et al.
Publicado: (2010)